JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB257532

Human MBD1 knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

MBD1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

View Alternative Names

CXXC 3, CXXC-type zinc finger protein 3, MBD1_HUMAN, MECP1 COMPLEX, Methyl CpG binding domain protein 1 isoform PCM1, Methyl CpG binding protein splice variant 1, Methyl CpG binding protein splice variant 2, Methyl CpG binding protein splice variant 3, Methyl CpG binding protein splice variant 4, Methyl-CpG-binding domain protein 1, Methyl-CpG-binding protein MBD1, Protein containing methyl-CpG-binding domain 1, RFT, Regulator of fibroblast growth factor 2 (FGF 2) transcription, The regulator of fibroblast growth factor 2(FGF 2) transcription

1 Images
Sanger Sequencing - Human MBD1 knockout HeLa cell lysate (AB257532)
  • Sanger seq

Unknown

Sanger Sequencing - Human MBD1 knockout HeLa cell lysate (AB257532)

Homozygous : 1 bp insertion in exon 2

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 2.

Disease

Adenocarcinoma

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab257532-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human MBD1 knockout HeLa cell lysate", "number":"AB257532-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB257532-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
MBD1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Methyl-CpG binding domain protein 1 (MBD1) also known as CXXC-type and BYE1 domain containing 1 recognizes and binds to methylated CpG sites in the DNA. This protein has a molecular weight of approximately 70 kDa. MBD1 is expressed widely in human tissues with higher levels detectable in the brain particularly the cerebral cortex. It acts within the nucleus where it functions as an important participant in the regulation of gene expression through DNA methylation.
Biological function summary

MBD1 influences the repression or activation of genomic transcription. It binds to methylated DNA and interacts with other proteins including methyl CpG binding proteins to form transcriptional repression complexes. This activity plays a role in gene silencing and modulation. MBD1 ensures proper interpretation of epigenetic marks therefore sustaining cellular identity and lineage commitment. In some cells MBD1 also engages with chromatin remodeling complexes to influence chromatin structure.

Pathways

MBD1 plays a significant role in the epigenetic and transcription regulation pathways. It is directly involved in DNA methylation processes interacting with histone deacetylases such as HDAC1 and other chromatin-modifying proteins. The pathway provides an important mechanism for long-term transcriptional silencing affecting developmental processes and cellular differentiation through methylation-dependent transcriptional regulation. MBD1 shares pathway interactions with proteins like MeCP2 highlighting interconnected roles in maintaining DNA methylation landscapes.

MBD1 has links to neurological disorders and cancer. It shows associations with Rett syndrome a neurodevelopmental disorder through its interaction with other methyl CpG binding proteins. Mutations or dysregulation in MBD1’s function can disrupt normal methylation patterns contributing to gene expression changes seen in disease states. In cancer aberrant MBD1 expression may lead to inappropriate gene silencing impacting tumor suppressor genes. Many cancers including glioblastoma exhibit altered MBD1 expression levels implicating its role in tumorigenesis.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com